Overview
- Eli Lilly’s stock rose 39% in 2025 on strong demand for its GLP‑1 injectables Mounjaro and Zepbound.
- Novo Nordisk launched a GLP‑1 pill in early 2026, creating a fresh competitive threat to Lilly’s franchise.
- Eli Lilly plans to introduce its own GLP‑1 pill, signaling a potential response to Novo’s early move.
- Lilly now trades at about 50 times earnings versus roughly 28 for the S&P 500, raising valuation concerns.
- Pfizer is pitched as a lower‑valued alternative at about 15 times earnings after shelving its internal GLP‑1, pursuing an acquisition for a new pipeline and a distribution pact for a Chinese GLP‑1 pill if approved.